HELDIN; Carl-Henrik

Patent Applications and Registrations

Patent applications and USPTO patent grants for HELDIN; Carl-Henrik.The latest application filed is for "therapeutic and prophylactic agent for glioma, brain tumor malignancy marker, brain tumor prognostic marker, method for determining malignancy and prognosis of brain tumor and antibody inhibiting tumor proliferation".

Company Profile

2.33.23

HELDIN; Carl-Henrik - Tokyo JP
Heldin; Carl-Henrik - Uppsala DE
Heldin; Carl-Henrik - Upsala SE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Therapeutic And Prophylactic Agent For Glioma, Brain Tumor Malignancy Marker, Brain Tumor Prognostic Marker, Method For Determining Malignancy And Prognosis Of Brain Tumor And Antibody Inhibiting Tumor Proliferation App 20220105122 - MIYAZONO; Kohei ; et al.	2022-04-07
Cleavage inhibitors of transforming growth factor beta type I receptor and uses thereof in cancer therapy Grant 9,296,818 - Landstrom , et al. March 29, 2	2016-03-29
Methods and materials related to hair pigmentation and cancer Grant 9,096,901 - Andersson , et al. August 4, 2	2015-08-04
Cleavage Inhibitors Of Transforming Growth Factor Beta Type I Receptor And Uses Thereof In Cancer Therapy App 20140377268 - Landstrom; Marene Inga-Britt ; et al.	2014-12-25
Cleavage Inhibitors Of Transforming Growth Factor Beta Type I Receptor And Uses Thereof In Cancer Therapy App 20140140998 - Landstrom; Marene Inga-Britt ; et al.	2014-05-22
Methods And Materials Related To Hair Pigmentation And Cancer App 20130004520 - Andersson; Leif ; et al.	2013-01-03
Methods and materials related to grey alleles Grant 8,278,043 - Andersson , et al. October 2, 2	2012-10-02
Antibodies which bind specifically to activin receptor like kinase 3 Grant 8,080,639 - Miyazono , et al. December 20, 2	2011-12-20
Activin receptor-like kinase-1 proteins having serine-threonine kinase domains Grant 7,932,351 - Miyazono , et al. April 26, 2	2011-04-26
Activin receptor-like kinases, proteins having serine threonine kinase domains and their use App 20100330657 - Miyazono; Kohei ; et al.	2010-12-30
Methods And Materials Related To Hair Pigmentation And Cancer App 20100285462 - Andersson; Leif ; et al.	2010-11-11
Combination comprising a signal transduction inhibitor and an epothilone derivative Grant 7,723,339 - Brandt , et al. May 25, 2	2010-05-25
Antibodies which bind specifically to activin receptor like kinases Grant 7,592,428 - Miyazono , et al. September 22, 2	2009-09-22
Activin receptor-like kinases, proteins having serine threonine kinase domains and their use App 20070203329 - Miyazono; Kohei ; et al.	2007-08-30
Platelet-derived growth factor D, DNA coding therefor, and uses thereof App 20070042413 - Eriksson; Ulf ; et al.	2007-02-22
Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor App 20070021327 - Pietras; Kristian ; et al.	2007-01-25
Platelet-derived growth factor D, DNA coding therefor, and uses thereof Grant 7,148,037 - Eriksson , et al. December 12, 2	2006-12-12
Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor Grant 7,141,375 - Pietras , et al. November 28, 2	2006-11-28
Methods of identifying morphogen receptor-binding analogs Grant 7,067,260 - Dijke , et al. June 27, 2	2006-06-27
Antibodies which bind specifically to activin receptor-like kinases Grant 6,982,319 - Miyazono , et al. January 3, 2	2006-01-03
Combination for the treatment of endothelial damage Grant 6,974,816 - Alitalo , et al. December 13, 2	2005-12-13
Methods of antagonizing morphogens App 20050233379 - ten Dijke, Peter ; et al.	2005-10-20
Recombinant PDGF A-chain homodimers and methods of use Grant 6,939,849 - Heldin , et al. September 6, 2	2005-09-06
TGFbeta signaling inhibitors App 20050136043 - Yakymovych, Ihor ; et al.	2005-06-23
Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor App 20040224335 - Pietras, Kristian ; et al.	2004-11-11
Combination comprising a signal transduction inhibitor and an epothilone derivative App 20040132754 - Brandt, Ralf ; et al.	2004-07-08
Platelet-derived growth factor D Grant 6,706,687 - Eriksson , et al. March 16, 2	2004-03-16
Method for treatment of tumors using nucleic acid ligands to PDGF Grant 6,699,843 - Pietras , et al. March 2, 2	2004-03-02
Smad associating polypeptides Grant 6,673,570 - Itoh , et al. January 6, 2	2004-01-06
Morphogenic protein-specific cell surface receptors and uses therefor Grant 6,632,618 - Dijke , et al. October 14, 2	2003-10-14
PARG, a GTPase activating protein which interacts with PTPL1 App 20030166232 - Saras, Jan ; et al.	2003-09-04
Method for identifying compounds that affect Smad7 binding Grant 6,605,443 - Nakao , et al. August 12, 2	2003-08-12
Combination for the treatment of endothelial damage App 20030099687 - Alitalo, Kari ; et al.	2003-05-29
Platelet-derived growth factor D, DNA coding therefor, and uses thereof App 20020164710 - Eriksson, Ulf ; et al.	2002-11-07
Platelet-derived growth factor C, DNA coding therefor, and uses thereof App 20020164687 - Eriksson, Ulf ; et al.	2002-11-07
Morphogenic protein-specific cell surface receptors and uses therefor App 20020155500 - Dijke, Peter ten ; et al.	2002-10-24
Smad2 phosphorylation and interaction with Smad4 App 20020146774 - Souchelnytskyi, Serhiy ; et al.	2002-10-10
Antibodies which bind specifically to activin receptor like kinases App 20020123139 - Miyazono, Kohei ; et al.	2002-09-05
Method for treatment of tumors using nucleic acid ligands to PDGF App 20020034506 - Pietras, Kristian ; et al.	2002-03-21
Isolated nucleic acid molecules which encode activin-receptor like kinases, expression vectors and cells containing these Grant 6,331,621 - Miyazono , et al. December 18, 2	2001-12-18
Isolated nucleic acid molecules encoding Smad7 Grant 6,251,628 - Nakao , et al. June 26, 2	2001-06-26
Activin receptor-like kinases, ALK-3 and ALK-6, and nucleic acids encoding them Grant 6,207,814 - Miyazono , et al. March 27, 2	2001-03-27
Smad2 phosphorylation and interaction with Smad4 Grant 6,103,869 - Souchelnytokyi , et al. August 15, 2	2000-08-15
Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides Grant 5,863,738 - Dijke , et al. January 26, 1	1999-01-26
Isolated nucleic acid encoding receptor-like TGF-.beta.1 binding protein Grant 5,731,200 - Ichijo , et al. March 24, 1	1998-03-24
Isolated, large latent complexes of TGF-.beta.2 and TGF-.beta.3, and new binding protein for latent form TGF-.beta.1, TGF-.beta.2 and TGF-.beta.3 LTBP-2 Grant 5,346,993 - Miyazono , et al. September 13, 1	1994-09-13
Platelet derived growth factor agonists Grant 5,326,695 - Andersson , et al. July 5, 1	1994-07-05
Isolated, large latent complexes of TGF-.beta.2 and TGF-.beta.3, and new binding protein for latent form TGF-.beta.1, TGF-.beta.2 and TGF-.beta.3 LTBP-2 Grant 5,280,109 - Miyazono , et al. January 18, 1	1994-01-18
Substantially pure receptor like TGF-.beta. 1 binding molecules and uses thereof Grant 5,229,495 - Ichijo , et al. July 20, 1	1993-07-20
DNA encoding platelet derived endothelial cell growth factor (PD-ECGF) Grant 5,227,302 - Heldin , et al. July 13, 1	1993-07-13
Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors Grant 5,219,759 - Heldin , et al. June 15, 1	1993-06-15
Isolated nucleotide sequence expressing human transforming growth factor-.beta.1-binding protein Grant 5,177,197 - Kanzaki , et al. January 5, 1	1993-01-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.